跳到主要內容
Quest Diagnostics Home.

我們可以為您提供支持,因為患者恢複預防性護理

While every health system has its own approach to handling the return to preventive and elective patient care during the COVID-19 pandemic, rest assured we are prepared to continue to support your organization, physicians, and patients in whatever capacity you may need.

\r\n"}}" id="text-1238ff1cc2" class="cmp-text">

雖然每個衛生係統在Covid-19流行期間有自己的處理返回預防和選擇性患者護理的方法,但請放心,我們準備繼續支持您的組織,醫生和患者以任何可能需要的能力。

幫助您管理轉型到Postpandemic Care Diagnostics

準備好Covid-19創建的新醫療保健需求

The COVID-19 pandemic has resulted in a 46% decline in identifying new cancer diagnoses in the US, causing delayed delivery of treatment. Urgent action is needed to avoid a potential increase in cancer deaths due to delayed diagnoses.1

\r\n"}}" id="text-43bae562d2" class="cmp-text">

Covid-19大流行導致在美國鑒定新的癌症診斷時導致46%下降,導致延遲遞送治療。需要采取緊急行動以避免由於延遲診斷而導致癌症死亡的潛在增加。1

According to provisional data, in 2020, there were notable changes in the number and ranking of deaths compared with 2019. Heart disease-related deaths increased by 4.8%, the largest increase in heart disease deaths since 2012. Increases in heart disease, Alzheimer's disease, and diabetes also reflect disruptions in healthcare that hampered early detection and disease management.2

\r\n"}}" id="text-cda38a1825" class="cmp-text">

根據臨時數據,在2020年,與2019年相比,死亡人數和排名有顯著的變化。心髒病相關的死亡增加了4.8%,自2012年以來的最大增加了心髒病死亡。心髒病的增加,阿爾茨海默病,糖尿病也反映了醫療保健的中斷,阻礙了早期檢測和疾病管理。2

Clinical drug testing decreased up to 70% during the pandemic, while positivity for nonprescribed drugs and dangerous drugs in combination nearly doubled. These trends indicate an unmet need for healthcare and public health resources that address the convergence of the drug epidemic and COVID-19 pandemic.3

\r\n"}}" id="text-cde358af51" class="cmp-text">

臨床藥物測試在大流行期間減少了70%,而非資格的藥物和危險藥物的陽性差異幾乎翻了一番。這些趨勢表明,對醫療保健和公共衛生資源的未滿足需要解決毒品流行病和Covid-19大流行的收斂性。3.

There is a growing body of evidence of a high prevalence of blood clots, strokes, heart attacks, and organ failure among patients infected with SARS-CoV-2 (COVID-19).4

\r\n"}}" id="text-f749b34d63" class="cmp-text">

患有SARS-COV-2(Covid-19)感染的患者的血凝塊,中風,心髒病發作和器官衰竭的血凝血,中風,心髒病發作和器官衰竭的患者的越來越多的證據。4.

The number of positive Hepatitis C (HCV) RNA diagnostic test results and medication prescriptions were 40% lower than the previous year, according to an early pandemic study. This was attributed to patients not accessing healthcare services for potentially life-saving treatment and care during the early months of the pandemic.5

\r\n"}}" id="text-63cfa40e5e" class="cmp-text">

根據早期大流行研究,陽性丙型肝炎(HCV)RNA診斷試驗結果和藥物處方的數量比上年低40%。這歸因於在大流行早期的潛在救生治療和護理的患者中歸因於沒有訪問醫療保健服務。5.

At least 1 in 7 patients with COVID-19 were found to be additionally infected with a secondary bacterial infection. Of the fatalities during the SARS-CoV-2 epidemic, 50% were caused by untreated or untreatable secondary bacterial infections, in most cases in the lung.6

\r\n"}}" id="text-8ed1abeb5a" class="cmp-text">

發現至少有1例Covid-19患者另外感染二次細菌感染。在SARS-COV-2流行病中的死亡率,50%是由未經治療或無法治療的二級細菌感染引起的,在肺部大多數情況下。6.

1 in 3 patients with COVID-19 were diagnosed with a neurological or psychiatric disorder within 6 months of infection. A study of over 230,000 patients shows the potential detriment to brain health following a COVID-19 diagnosis.7

\r\n"}}" id="text-3187b52973" class="cmp-text">

在3例Covid-19患者中,在感染的6個月內被診斷出患有神經係統或精神疾病。在Covid-19診斷後,對超過230,000名患者的研究表明對腦部健康的潛在損害。7.

現在是確保您的實驗室盡可能高效的時間

Quest can provide insights that help lab managers, pathologists, and clinicians collaborate to drive targeted enhancements in test selection and interpretation, and improvements in lab operations and patient outcomes.

\r\n

Our experts can review your lab operations and help implement changes to increase lab efficiency and productivity, helping you manage post-COVID test volumes. Opportunities for efficiency include increasing process standardization, moving high-cost testing off-site, balancing staffing with volume and workflow, and more.

\r\n"}}" id="text-9db598c183" class="cmp-text">

Quest可以提供幫助,幫助實驗室經理,病理學家和臨床醫生合作,以推動測試選擇和解釋中的有針對性的增強,以及實驗室運營和患者結果的改進。

我們的專家可以審查您的實驗室操作,並幫助實施更改以提高實驗室效率和生產力,幫助您管理Covid測試卷。效率的機會包括增加流程標準化,從現場移動高成本測試,平衡員工和工作流程,更多。

延遲HCV檢測和治療可能導致發病率和死亡率增加

新的研究表明,2020年7月20日陽性HCV RNA診斷測試結果和藥物處方的數量下降了40%,而2018/2019的同月則歸因於未獲得醫療保健服務的患者,以便在早期潛在的救命治療和護理。多個月的大流行。

查看摘要

Covid-19測試

A molecular test is available to test symptomatic patients for COVID-19. Through qualitative multi-target molecular diagnostics, this testing option helps to detect the presence of SARS-CoV-2.

\r\n"}}" id="text-af2c190231" class="cmp-text">

一種分子試驗可用於測試Covid-19的症狀患者。通過定性的多目標分子診斷,該測試選項有助於檢測SARS-COV-2的存在。

Cotesting options can help differentially detect or evaluate the pathogen(s) responsible for a patient’s respiratory infection. These cotesting options include many clinical advantages including, but not limited to, collecting a single specimen, potentially minimizing patient discomfort and expediting time to diagnosis.

\r\n\r\n"}}" id="text-a305b33bff" class="cmp-text">

Cotesting選項可以幫助差異地檢測或評估負責患者呼吸道感染的病原體。這些Cotesting選項包括許多臨床優勢,包括但不限於收集單一標本,可能最小化患者的不適和快速診斷時間。

The following testing options can help identify recent or prior infection with SARS-CoV-2 (which may be resolved or is still resolving):

\r\n\r\n"}}" id="text-85fe9482b1" class="cmp-text">

以下測試選項可以幫助識別近期或以SARS-COV-2(可能已解決或仍在解析)的先前感染):

1Kaufman HW,Chen Z,Niles J,等。2019年冠狀病毒疾病前後新發現癌症患者數量的變化(Covid-19)大流行。Jama Netw開放。2020; 3(8):E2017267。DOI:10.1001 / JamanetWorkopen.202010.172677

2Ahmad FB,安德森RN。2020年美國死亡原因。賈瑪。2021; 325(18):1829-1830。DOI:10.1001 / JAMA.2021.5469

3.尼爾斯JK,Gudin J,Radcliff J,Kaufman HW。Covid-19大流行病中的阿片類疫情:2020年藥物檢測。popul健康管理。2021; 24(S1):S43-S51。

4.varga z,flammer aj,steiger p等人。Covid-19中內皮細胞感染和內皮炎。蘭蔻。2020; 395(10234):1417-1418。DOI:10.1016 / S0140-6736(20)30937-5

5.Kaufman HW,Bull-Otterson L,Meyer III WA,等。在Covid-19流行期間降低丙型肝炎測試和治療。am j prev med。EPUB 5月10日,2021.訪問8月6日,2021. DOI:10.1016 / J.AMEPRE.2021.03.011

6.Manohar P,Loh B,Athira S等人。肺病毒疾病中的繼發細菌感染:噬菌體治療劑作為抗生素的替代品?前微生物。2020; 11:1434。DOI:10.3389 / FMICB.2020.01434

7.Taquet M,Geddes Jr,Husain M等人。Covid-19的236,379幸存者6個月的神經和精神病成果:使用電子健康記錄的回顧性隊列研究。柳葉賽兵精神病學。2021; 8(5):416-427。DOI:10.1016 / S2215-0366(21)00084-5

•Cepheid SARS-COV-2,流感A / B和RSV測試,COBAS®SARS-COV-2和流感A / B檢驗以及Quest SARS-COV-2 RT-PCR試驗和其他分子測試(“測試“)沒有被FDA清除或批準。

•Roche®測試已僅用於檢測來自SARS-COV-2病毒,流感病毒和流感B病毒的RNA,而不是任何其他病毒或病原體。

•Cepheid SARS-COV-2,流感A / B和RSV測試已被授權用於同時定性檢測和分化來自SARS-COV-2,流感A,流感B和呼吸合胞病毒(RSV)的核酸,而不是任何其他病毒或病原體;

•Cepheid SARS-COV-2,流感A / B和RSV測試僅授權宣言的持續時間,即情況存在證明授權在部分診斷中授權用於審查和/或診斷Covid-19下的Covid-195.6.4.(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

•羅氏測試僅授權宣布的持續時間,即在第564條第564條下的SARS-COV-2病毒,流感A和流感B檢測和分化的體外診斷授權的情況證明了情況。)(1) of the Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the authorized is terminated or revoked sooner.

•該試驗已由FDA授權,根據1988年(CLIA)的臨床實驗室改進修正案,42 U.S.C.認證的實驗室。§263A,進行中等和高複雜性測試。

•任務測試和其他分子測試僅授權檢測來自SARS-COV-2的核酸,而不是任何其他病毒或病原體。

•Quest測試和其他分子測試僅授權宣布的持續時間,即根據第564(b)(b)(b)(b)(b)(1)條的審查和/或診斷COVID-19的授權the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

支持您的係統

當您努力跟上正在進行的Covid-19護理時,追趕延期護理會對臨床工作人員產生進一步的壓力。

看看我們如何提供幫助
Baidu
map